Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

634 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
Rosti G, Martinelli G, Bassi S, Amabile M, Trabacchi E, Giannini B, Cilloni D, Izzo B, De Vivo A, Testoni N, Cambrin GR, Bonifazi F, Soverini S, Luatti S, Gottardi E, Alberti D, Pane F, Salvatore F, Saglio G, Baccarani M; Study Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia; Writing Committee, Italian Cooperative Study Group for Chronic Myeloid Leukemia. Rosti G, et al. Among authors: saglio g. Blood. 2004 Mar 15;103(6):2284-90. doi: 10.1182/blood-2003-07-2575. Epub 2003 Nov 26. Blood. 2004. PMID: 14645009 Free article. Clinical Trial.
Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib.
Soverini S, Martinelli G, Amabile M, Poerio A, Bianchini M, Rosti G, Pane F, Saglio G, Baccarani M; Italian Cooerative Study Group on Chronic Myeloid Leukemia; European LeukemiaNet-6th Framework Program of the European Community. Soverini S, et al. Among authors: saglio g. Clin Chem. 2004 Jul;50(7):1205-13. doi: 10.1373/clinchem.2004.031112. Epub 2004 Apr 23. Clin Chem. 2004. PMID: 15107311
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia.
Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, de Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G; GIMEMA Working Party on Chronic Myeloid Leukemia. Baccarani M, et al. Among authors: saglio g. Blood. 2004 Dec 15;104(13):4245-51. doi: 10.1182/blood-2004-03-0826. Epub 2004 Aug 19. Blood. 2004. PMID: 15319292 Free article. Clinical Trial.
Glivec and CML: a lucky date.
Saglio G, Cilloni D, Rancati F, Boano L. Saglio G, et al. J Biol Regul Homeost Agents. 2004 Apr-Jun;18(2):246-51. J Biol Regul Homeost Agents. 2004. PMID: 15739279 Review.
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A, Giannini B, Trabacchi E, Castagnetti F, Testoni N, Luatti S, de Vivo A, Cilloni D, Izzo B, Fava M, Abruzzese E, Alberti D, Pane F, Saglio G, Baccarani M. Soverini S, et al. Among authors: saglio g. J Clin Oncol. 2005 Jun 20;23(18):4100-9. doi: 10.1200/JCO.2005.05.531. Epub 2005 May 2. J Clin Oncol. 2005. PMID: 15867198 Clinical Trial.
634 results